Qiagen N.V. $QGEN Shares Bought by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC boosted its position in shares of Qiagen N.V. (NYSE:QGEN) by 5.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,874,356 shares of the company’s stock after buying an additional 141,393 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Qiagen were worth $133,140,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in QGEN. Voya Investment Management LLC boosted its position in Qiagen by 52.3% during the first quarter. Voya Investment Management LLC now owns 245,657 shares of the company’s stock worth $9,845,000 after acquiring an additional 84,332 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in Qiagen by 117.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,252,948 shares of the company’s stock valued at $60,217,000 after acquiring an additional 675,498 shares during the last quarter. Callan Family Office LLC purchased a new position in Qiagen in the 2nd quarter worth approximately $304,000. Swiss National Bank boosted its holdings in shares of Qiagen by 5.9% during the 2nd quarter. Swiss National Bank now owns 655,270 shares of the company’s stock worth $31,388,000 after purchasing an additional 36,361 shares during the last quarter. Finally, Moors & Cabot Inc. boosted its holdings in shares of Qiagen by 136.6% during the 2nd quarter. Moors & Cabot Inc. now owns 197,958 shares of the company’s stock worth $9,514,000 after purchasing an additional 114,289 shares during the last quarter. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Qiagen Price Performance

Qiagen stock opened at $45.33 on Wednesday. The company’s 50 day simple moving average is $45.98 and its 200-day simple moving average is $47.09. The company has a debt-to-equity ratio of 0.45, a quick ratio of 2.30 and a current ratio of 2.60. Qiagen N.V. has a 1 year low of $37.63 and a 1 year high of $51.88. The company has a market capitalization of $10.08 billion, a price-to-earnings ratio of 24.64, a price-to-earnings-growth ratio of 2.33 and a beta of 0.67.

Qiagen shares are set to reverse split on Thursday, January 8th. The 19-20 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Wednesday, January 7th.

Qiagen (NYSE:QGEN) last issued its quarterly earnings data on Thursday, November 6th. The company reported $0.61 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.03. The business had revenue of $532.58 million during the quarter, compared to analysts’ expectations of $525.68 million. Qiagen had a return on equity of 14.80% and a net margin of 19.58%.The company’s revenue was up 6.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.57 earnings per share. As a group, equities research analysts expect that Qiagen N.V. will post 2.26 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have issued reports on the company. Citigroup cut Qiagen from a “buy” rating to a “neutral” rating and dropped their target price for the company from $55.00 to $50.00 in a report on Thursday, December 11th. Weiss Ratings reissued a “hold (c)” rating on shares of Qiagen in a report on Monday. Wall Street Zen upgraded shares of Qiagen from a “hold” rating to a “buy” rating in a research report on Sunday, December 21st. Finally, Barclays reiterated an “overweight” rating and issued a $55.00 target price (up from $53.00) on shares of Qiagen in a report on Monday, December 15th. Two investment analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Qiagen presently has an average rating of “Hold” and a consensus price target of $49.61.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.